Showing results (21-30 of 128) with videos related to
Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|December 21, 2019
Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modellingFazila Bunglawala, Rajith K R Rajoli, Mark Mirochnick, et al.Journal of the International AIDS Society|November 14, 2014
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approachLaura Dickinson, Alan Winston, Marta Boffito, et al.Clinical Pharmacokinetics|September 8, 2016
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on CytochromesCatia Marzolini, Rajith Rajoli, Manuel Battegay, et al.Frontiers in Pharmacology|January 2, 2023
Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modellingSandra Grañana-Castillo, Maiara Camotti Montanha, Rachel Bearon, et al.Clinical Pharmacokinetics|September 24, 2014
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapineAlessandro Schipani, David Back, Andrew Owen, et al.The Journal of Antimicrobial Chemotherapy|December 30, 2015
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approachLaura Dickinson, Alan Winston, Marta Boffito, et al.Clinical Pharmacology and Therapeutics|November 14, 2019
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted LopinavirTeerachat Saeheng, Kesara Na-Bangchang, Marco Siccardi, et al.Clinical Pharmacokinetics|October 5, 2019
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the ElderlyFelix Stader, Hannah Kinvig, Melissa A Penny, et al.Pharmacology Research & Perspectives|October 4, 2017
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation ratesChristina Chan, Philip Martin, Neill J Liptrott, et al.Antimicrobial Agents and Chemotherapy|May 20, 2020
Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic ModellingRajith K R Rajoli, Zach R Demkovich, Charles Flexner, et al.Pageof 13